A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä
Alogliptin after Acute Coronary Syndrome in Patients with Type 2 Diabetes
Tekijät: White WB, Cannon CP, Heller SR, Nissen SE, Bergenstal RM, Bakris GL, Perez AT, Fleck PR, Mehta CR, Kupfer S, Wilson C, Cushman WC, Zannad F, EXAMINE Investigators
Kustantaja: MASSACHUSETTS MEDICAL SOC
Julkaisuvuosi: 2013
Journal: New England Journal of Medicine
Tietokannassa oleva lehden nimi: NEW ENGLAND JOURNAL OF MEDICINE
Lehden akronyymi: NEW ENGL J MED
Numero sarjassa: 14
Vuosikerta: 369
Numero: 14
Aloitussivu: 1327
Lopetussivu: 1335
Sivujen määrä: 9
ISSN: 0028-4793
DOI: https://doi.org/10.1056/NEJMoa1305889
Tiivistelmä
ConclusionsAmong patients with type 2 diabetes who had had a recent acute coronary syndrome, the rates of major adverse cardiovascular events were not increased with the DPP-4 inhibitor alogliptin as compared with placebo. (Funded by Takeda Development Center Americas; EXAMINE ClinicalTrials.gov number, NCT00968708.)
ConclusionsAmong patients with type 2 diabetes who had had a recent acute coronary syndrome, the rates of major adverse cardiovascular events were not increased with the DPP-4 inhibitor alogliptin as compared with placebo. (Funded by Takeda Development Center Americas; EXAMINE ClinicalTrials.gov number, NCT00968708.)
Turun yliopiston Tutkimustietojärjestelmän portaali